LUCIUS 卢修斯 卡匹色替 卡帕塞替尼 Capivasertib乳腺癌

卡匹色替

美国FDA批准上市产品,疗效确切

另译为

卡帕塞替尼

卢修斯制药(老挝)有限公司出品
老挝国家食药监局批准上市

Capivasertib

老挝国家药检所检测认证

Composition:

Each film-coated tablet contains Capivasertib .. 160 mg

乳腺癌

LuciCapiva is a kinase inhibitor indicateo, in

LUCIUS

comoination with Fulvestrant for the treatment of adult
e recepfor (HR).positive, human

PHARMACEUTICALS

epidermal growth factor receptor 2(HER2)-negative.

locany aTUDTEN-Alterations as detecicu

d or matactatie hrasst eancar sith ona

LuciCapiva

least one endoerncasion on a

In the metastafic
regimen in the metastatic
or recurrence on or within 12 months of completin

adjuvant theraoy
Desage and Uses
.Select patients for the treatment of HR-nosttive.

Capivasertib Tablets

FDA批准

advanced or metastatic breast cancer
Dased on the presence of one or mor
piysgnetic alterations in tumor tissue:

.See Full Preseribine Information for LuciCapiva

160mg

Recommended dosane reductions for adverse reactions

Storagptin adru nlsnas
2gc- a dry place and store at:20C to25C.
Warning:
Keep medicine our of reach of Children. Do not administer

Rx only

LuciCapiva during Pregnaney andLactation,
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by

权威认证

LUCIUS

ang village, Xaythany district, Vientiane
www.luciosla
oTegstercd pnysicians only, and as directed
oy the physician

64 Tablets

口碑质量

适应症:
卡帕塞替尼与氟维司群联合适用于治疗激素受体(HR)阳性、人类
表皮生长因子受体2(HER2)阴性、局部晚期或转移性乳腺癌的成

年患者,这些患者有一种或多种PIK3CA/AKT1/PTEN改变,在转
移性乳腺癌中接受至少一种内分泌治疗方案后出现进展,或在完
成辅助治疗时或完成辅助治疗后12个月内出现复发。
推荐剂量:
每日口服两次,每次400毫克,可与食物同服或单独服用,连续服
用4天,然后停药3天。